AR044774A1 - Composiciones farmaceuticas de atorvastatina - Google Patents

Composiciones farmaceuticas de atorvastatina

Info

Publication number
AR044774A1
AR044774A1 ARP040102008A ARP040102008A AR044774A1 AR 044774 A1 AR044774 A1 AR 044774A1 AR P040102008 A ARP040102008 A AR P040102008A AR P040102008 A ARP040102008 A AR P040102008A AR 044774 A1 AR044774 A1 AR 044774A1
Authority
AR
Argentina
Prior art keywords
atorvastatin
compositions
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
Prior art date
Application number
ARP040102008A
Other languages
English (en)
Spanish (es)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AR044774A1 publication Critical patent/AR044774A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
ARP040102008A 2003-06-12 2004-06-10 Composiciones farmaceuticas de atorvastatina AR044774A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47811903P 2003-06-12 2003-06-12

Publications (1)

Publication Number Publication Date
AR044774A1 true AR044774A1 (es) 2005-10-05

Family

ID=33551806

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102008A AR044774A1 (es) 2003-06-12 2004-06-10 Composiciones farmaceuticas de atorvastatina

Country Status (15)

Country Link
EP (1) EP1635814A1 (pt)
JP (1) JP2006527260A (pt)
KR (1) KR100814218B1 (pt)
CN (1) CN100434069C (pt)
AR (1) AR044774A1 (pt)
AU (1) AU2004246868B2 (pt)
BR (1) BRPI0411344A (pt)
CA (1) CA2465565A1 (pt)
CO (1) CO5650230A2 (pt)
MX (1) MXPA05013281A (pt)
NO (1) NO20060022L (pt)
NZ (1) NZ543337A (pt)
RU (1) RU2332211C2 (pt)
TW (1) TW200503690A (pt)
WO (1) WO2004110431A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
WO2009000286A1 (en) * 2007-06-25 2008-12-31 Parmatheen S.A. Improved pharmaceutical formulation containing an hmg-coa reductase inhibitor and method for the preparation thereof
KR20100125346A (ko) * 2008-02-27 2010-11-30 토멘 메디칼 아게 임플란트 및 이의 제조 방법
AU2009292615B2 (en) * 2008-09-17 2015-12-03 Mylan Inc. Granulates, process for preparing them and pharmaceutical products containing them
RU2404767C1 (ru) * 2009-08-11 2010-11-27 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма, обладающая гиполипидемической и гипохолестеринемической активностью, и способ ее получения
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
RU2014124118A (ru) 2011-11-15 2015-12-27 Др. Редди'С Лабораторис Лтд. Фармацевтические препараты, включающие аторвастатин и глимепирид
LT3470063T (lt) * 2012-11-02 2025-02-10 Vertex Pharmaceuticals Incorporated Farmacinės kompozicijos, skirtos cftr nulemtų ligų gydymui
CN104069078B (zh) * 2014-05-22 2019-06-11 西藏九瑞健康股份有限公司 阿托伐他汀钙药物组合物及其制备方法
CA2954840A1 (en) * 2014-07-25 2016-01-28 Novartis Ag Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
KR101658350B1 (ko) * 2015-02-06 2016-09-30 경성대학교 산학협력단 고지혈증 치료에 유용한 약학 조성물
WO2016145132A1 (en) * 2015-03-12 2016-09-15 Fmc Corporation Solid dispersions
JPWO2017170858A1 (ja) 2016-03-31 2019-02-14 インターセプト ファーマシューティカルズ， インコーポレイテッド 溶出性に優れた経口製剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3254219B2 (ja) * 1993-01-19 2002-02-04 ワーナー−ランバート・コンパニー 安定な経口用のｃｉ−９８１製剤およびその製法
JPH06242003A (ja) * 1993-02-12 1994-09-02 Nkk Corp 鉄鋼中のアルミナの粒度測定方法
JP3014040B2 (ja) * 1996-10-30 2000-02-28 信久 川野 食物繊維パン及びその製造法
CA2406574C (en) * 2000-04-10 2006-12-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
EP1226818A1 (en) * 2001-01-26 2002-07-31 Pfizer Products Inc. Pharmaceutical dosage forms with enhanced cohesive and compressibility properties
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
EP1291017A3 (en) * 2001-09-10 2003-07-02 Warner-Lambert Company Use of statins to inhibit formation of osteoclasts

Also Published As

Publication number Publication date
CN100434069C (zh) 2008-11-19
CO5650230A2 (es) 2006-06-30
BRPI0411344A (pt) 2006-07-11
RU2332211C2 (ru) 2008-08-27
NZ543337A (en) 2008-03-28
TW200503690A (en) 2005-02-01
KR100814218B1 (ko) 2008-03-17
CA2465565A1 (en) 2004-12-12
CN1805741A (zh) 2006-07-19
NO20060022L (no) 2006-01-03
WO2004110431A1 (en) 2004-12-23
AU2004246868B2 (en) 2008-01-17
MXPA05013281A (es) 2006-03-09
RU2005136745A (ru) 2006-07-27
JP2006527260A (ja) 2006-11-30
KR20060020666A (ko) 2006-03-06
AU2004246868A1 (en) 2004-12-23
EP1635814A1 (en) 2006-03-22

Similar Documents

Publication Publication Date Title
AR044774A1 (es) Composiciones farmaceuticas de atorvastatina
AR044775A1 (es) Composiciones farmaceuticas de atorvastatina
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
NO20082088L (no) Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer
TW200607807A (en) Macrocyclic beta-secretase inhibitors
ES2124372T3 (es) Composiciones de liberacion prolongada a base de morfina.
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
PA8587101A1 (es) Nuevos derivados de dihidropirimido [4,5-d] pirimidinona sustituida por amiino, fabricacion y uso de los mismos como agentes farmaceuticos
ATE360630T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
ATE407928T1 (de) Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung
CR8102A (es) Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
CL2009000241A1 (es) Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
GT200500098A (es) Nuevos compuestos
AR044660A1 (es) Composiciones farmaceuticas de atorvastatina
AR058780A1 (es) Imidazopirazinas como inhibidores de quinasas dependientes de ciclina
AR041089A1 (es) Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
MX2024013019A (es) Compuestos de heteroarilo para el tratamiento del dolor
PA8606201A1 (es) DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN
AR048336A1 (es) Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
MY133512A (en) Non-steroidal il-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors
AR030140A1 (es) Composiciones derivadas de la 2-piridinamina y metodos relacionados
SE0401655D0 (sv) New compounds
AR026911A1 (es) Preparado farmaceutica para el tratamiento de afecciones tumorales

Legal Events

Date Code Title Description
FB Suspension of granting procedure